Glaukos Corp
Atvērts
SektorsVeselības aprūpe
128.06 1.08
Pārskats
Akcijas cenas izmaiņa
24h
Min
126.69
Max
129.23
Ienākumi | 114M -20M |
|---|---|
Pārdošana | 7.5M 151M |
EPS | -0.18 |
Peļņas marža | -13.139 |
Darbinieki | 1,094 |
EBITDA | 123M -7M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +22.82% upside |
Nākamie ieņēmumi | 2026. g. 29. jūl. |
|---|
Tirgus kapitalizācija | 19M 7.2B |
|---|---|
Iepriekšējā atvēršanas cena | 126.98 |
Iepriekšējā slēgšanas cena | 128.06 |
Ziņu noskaņojums
By Acuity
26%
74%
60 / 342 Rangs Healthcare
Glaukos Corp Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.